TY - JOUR T1 - Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID 19 JF - medRxiv DO - 10.1101/2020.09.10.20191619 SP - 2020.09.10.20191619 AU - Carvallo Héctor AU - Hirsch Roberto AU - Farinella María Eugenia Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/15/2020.09.10.20191619.abstract N2 - From the first outbreak in Wuhan (China) in December 2019, until today the number of deaths worldwide due to the coronavirus pandemic exceeds eight hundred thousand people and the number of infected people arises to more than 25 million.No treatment tested worldwide has shown unquestionable efficacy in the fight against COVID 19, according to NICE reports.We have designed an experimental treatment called IDEA based on four affordable drugs already available on the market in Argentina, based on the following rationale: - Ivermectin solution at a relatively high dose to lower the viral load in all stages of COVID 19- Dexamethasone 4-mg injection, as anti-inflammatory drug to treat hyperinflammatory reaction to COVID-infection- Enoxaparin injection as anticoagulant to treat hypercoagulation in severe cases.- Aspirin 250-mg tablets to prevent hypercoagulation in mild and moderate casesExcept for Ivermection oral solution, which was used in a higher dose than approved for parasitosis, all other drugs were used in the already approved dose and indication. Regarding Ivermectin safety, several oral studies have shown it to be safe even when used at daily doses much higher than those approved already.A clinical study has been conducted on COVID-19 patients at Eurnekian Hospital in the Province of Buenos Aires, Argentina. The study protocol and its final outcomes are described in this article. Results were compared with published data and data from patients admitted to the hospital receiving other treatments.None of the patient presenting mild symptoms needed to be hospitalized. Only one patient died (0.59 % of all included patients vs. 2.1 % overall mortality for the disease in Argentina today; 3.1 % of hospitalized patients vs. 26.8 % mortality in published data). IDEA protocol appears to be a useful alternative to prevent disease progression of COVID-19 when applied to mild cases and to decrease mortality in patients at all stages of the disease with a favorable risk-benefit ratio.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04425863Funding StatementSome of the medicines were provided by Laboratorio Pablo Cassara S.R.L.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of the Hospital and the County Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request. ER -